A5049665809- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Economic and Financial Impacts of Cancer
- Maternal Mental Health During Pregnancy and Postpartum
- Cancer Treatment and Pharmacology
- Cancer-related molecular mechanisms research
- Cancer-related cognitive impairment studies
- Mobile Health and mHealth Applications
- MicroRNA in disease regulation
- Radiomics and Machine Learning in Medical Imaging
- Child and Adolescent Psychosocial and Emotional Development
- Brain Metastases and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Pancreatic and Hepatic Oncology Research
- Music Therapy and Health
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Circular RNAs in diseases
University Hospital Heidelberg
2018-2025
Heidelberg University
2015-2025
Frauenklinik Heidelberg
2020-2022
Universitäts Frauenklinik
2020-2022
National Center for Tumor Diseases
2016-2021
German Cancer Research Center
2021
Zimmer Biomet (Germany)
2019
Background Peripartum depression and anxiety disorders are highly prevalent correlated with adverse maternal neonatal outcomes. Antenatal care in Germany does not yet include structured screening effective low-threshold treatment options for women facing peripartum disorders. Mindfulness-based interventions (MBIs) increasingly becoming a focus of interest the management such patients. Studies have shown decrease pregnancy-related stress expectant mothers following mindfulness programs....
Abstract Neoadjuvant chemotherapy (NACT) in early breast cancer (EBC) enables vivo sensitivity testing and less radical surgery as compared to primary adjuvant (ACT). The aim of our study is illustrate trends systemic treatment EBC. analyzed usage time for patients with EBC treated at 104 German units between January 2008 December 2017. data were obtained through a quality‐controlled benchmarking process. Altogether, 124 084 included, whom 46 279 (37.3%) received chemotherapy. For 44 765...
Abstract Background The estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) statuses are frequently discordant between the primary tumor metastatic lesions in breast cancer. This can have important therapeutic implications. Patients methods In all, 541 patients with available from both lesion treated at Heidelberg Tuebingen University Hospitals 1982 2018 were included. Results Statistically significant discordance rates of 14% 32% found for ER PR. HER2...
Abstract Cell lines derived from circulating tumor cells (CTCs) in the blood provide important biological information on cancer metastasis. CTC-ITB-01 is a CTC cell line patient with metastatic estrogen receptor-alpha (ER-alpha) positive breast two months before death of patient. After LC-MC/MS based proteomics analysis CTC-ITB-01, we found extraordinary high levels poorly characterized protein SUSD2 (sushi domain-containing 2) CTC-ITB-01. Expression subsets CTCs was validated clinical...
The loss of breast cancer cell differentiation during metastatic progression leads to a down-regulation class 1 human leukocyte antigen (HLA) expression, which in turn hinders cytotoxic T lymphocytes from effectively preventing tumor proliferation. Consequently, one would expect that decreased HLA expression correlate with 5-year survival. However, estrogen receptor alpha (ESR1) is known be positively associated overall study aimed determine the levels HLA-A, HLA-B/C, and ESR1 assess their...
Background/Aim: Class 1 human leukocyte antigen (HLA) ensures that cytotoxic T lymphocytes (CTLs) attack tumor cells. As part of de-differentiation, the expression HLA on cell surface may decrease, which can facilitate growth. Therefore, reduced is generally negatively associated with overall survival (OS). The reverse true for programmed death protein (PD-1) and ligand (PD-L1). presence PD-1 PD-L1 cancer cells inhibits immune defense mechanisms against one would expect increased PD-1/PDL-1...
ObjectiveMeasuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint an intra-patient progression-free survival (PFS) ratio, defined as PFS interval associated with therapy (PFS2) divided by last prior systemic (PFS1), above 1.3 or, some studies, 1.33 or 1.5.MethodsTo investigate if concept ratios agreement actual response evaluations physicians, we conducted survey among members MASTER (Molecularly Aided Stratification...
Oligometastatic disease (OMD) and oligoprogressive (OPD) describe tumor states with a limited metastasization. In contrast to other states, treatment of OMD or OPD has not yet become common for breast cancer. We sought understand the outcomes toxicities this paradigm. retrospectively analyzed female cancer patients (≤3 metastases) (1 progressive lesion) who received stereotactic body radiotherapy (SBRT) their respective extracranial metastatic lesions between 01/2002 07/2019. Survival...
Abstract Purpose Breast cancer (BC) is the most common malignancy among women and prognosis strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) standard treatment for both locally advanced- early-stage triple-negative Her2-positive BC. Pathologic complete response (pCR) to NAC an important predictor of patient outcomes. Neutrophil-to-lymphocyte-ratio (NLR) in peripheral blood associated with various malignancies. Here, we investigated value pretreatment NLR as a...
Today, the decision to treat patients with chemotherapy for early breast cancer (EBC) is made based on patient's individual risk stratification and tumor biology. In cases indication, neoadjuvant application (NACT) preferred option in comparison primary surgery adjuvant (ACT). Age remains a relevant factor decision-making process. The aim of present study was illustrate impact age use systemic therapy clinical routine.The separately analyzed among six cohorts EBC who had been treated at 104...
Abstract Purpose As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall (OS), circulating tumor cells (CTCs) constitute a promising component developing liquid biopsy patients with metastatic breast cancer (MBC). The effects of HER2-targeted therapy such as trastuzumab, pertuzumab, T-DM1, lapatinib on CTC status longitudinal enumeration were assessed in this trial. Methods 264 MBC was analyzed prior to after 4 weeks new line palliative systemic...
Background Pregnant women are increasingly using mobile apps to access health information during the antenatal period. Therefore, digital solutions can potentially be used as monitoring instruments pregnancy. However, a main factor of success is high user engagement. Objective The aim this study was analyze engagement and factors influencing compliance in longitudinal targeting pregnant app with self-tracking. Methods Digitally collected data concerning demographics, medical history,...
Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients is thus considered an independent, negative prognostic factor. A clear decline CTCs observed who respond to systemic therapy. Nevertheless, decrease experiencing progression during therapy, too. This study aims determine the differences CTC responding therapy those whom progressing. Therefore, values were compared at start after one cycle a new line In all,...
Abstract Purpose Circulating miRNAs can provide valid prognostic and predictive information for breast cancer diagnosis subsequent management. They may comprise quintessential biomarkers that be obtained minimally invasively from liquid biopsy in metastatic patients. Therefore, they would clinically crucial monitoring therapy response, with the goal of detecting early relapse. This study investigated miRNA expression patients and/or late relapse, value assessing overall (OS) progression-free...
The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic predictive biomarker breast cancer (MBC). Expression levels of plasma miR-200 family were analyzed relationship systemic treatment, tumor cells (CTC) count, progression-free survival (PFS), overall (OS). miR-200a, miR-200b, miR-200c, miR-141, miR-429, CTC status (CTC-positive ≥ 5 CTC/7.5 mL)...
// Stefan Stefanovic 1, 2, * , Ralph Wirtz 3, Thomas M. Deutsch 2 Andreas Hartkopf 4 Peter Sinn 5 Zsuzsanna Varga 6 Bettina Sobottka Lakis Sotiris 3 Florin-Andrei Taran Christoph Domschke Andre Hennigs Sara Y. Brucker 7 Christof Sohn Florian Schuetz Schneeweiss and Markus Wallwiener 1 Department of Gynecology Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany National Center for Tumor Diseases (NCT) Stratifyer Molecular Pathology GmbH, 50935 Cologne, Women's Health,...
In cancer metastasis, single circulating tumor cells (CTCs) in the blood and disseminated (DTCs) bone marrow mediate metastasis. Because suitable biomarker proteins are lacking, CTCs DTCs with mesenchymal attributes difficult to isolate from bulk of normal cells. To establish a procedure allowing isolation such cells, we analyzed cell line BC-M1 established breast patient by stable isotope labeling amino acids culture (SILAC) mass spectrometry. We found high levels transmembrane protein CUB...
Background Early identification of quality life (QoL) loss and side effects is a key challenge in breast cancer therapy. Digital tools can be helpful components therapeutic support. Enable, smartphone app, was used multicenter, prospective randomized controlled trial 3 centers. The app simultaneously serves as therapy companion (eg, by displaying appointments), tool for documenting QoL enabling data collection questionnaires), documentation patient-reported effects. need digital continually...
One in eight women is diagnosed with breast cancer the course of their life. As systematic palliative treatment has only a limited effect on survival rates, concept health-related quality life (HRQoL) was developed for measurement patient-centered outcomes. Various studies have already demonstrated reliability paper-based patient-reported outcome (pPRO) and electronic (ePRO) surveys that 2 means assessment are equally valid.The aim this study to analyze acceptance evaluation tablet-based...
Background Health-related quality of life (HRQoL) is used to evaluate the treatment metastatic breast cancer. In a long-term therapy setting, HRQoL can be as an important benchmark for success. With help digital apps, monitoring extended more remote areas and administered on frequent basis. Objective This study aims 3 common questionnaires in metastasized cancer terms TTD digital, web-based setting. We further aim examine development different systemic groups each these evaluation...
Background/Aim: Loss of differentiation breast cancer cells in association with a down-regulated class I human leukocyte antigen (HLA) expression can lead to proliferation unhampered by cytotoxic T lymphocytes, which has been proven be prognostic relevance. The objective this study was determine the levels HLA-A and HLA-B/C metastatic (MBC) their usefulness for predicting 5-year survival. Materials Methods: This prospective double-blinded cohort analyzed patients starting new line therapy...
Hospital information systems (HIS) play a critical role in modern healthcare by facilitating the management and delivery of patient care services. We aimed to evaluate current landscape HIS specialty gynecology obstetrics Germany.An anonymous questionnaire was distributed via German Society Gynecology Obstetrics newsletter December 2022. The covered domains baseline demographic information, satisfaction with daily use, implementation, degree digitization.Ninety-one participants completed...